Core Insights - Jianfan Bio's case study has been included in the "Business for Good Case Collection 2025," highlighting its commitment to social responsibility and innovation in the medical technology sector [1] - The case focuses on over 20 years of "responsibility evolution," emphasizing the company's efforts to break foreign medical technology monopolies through independent innovation in blood purification technology [1] - The initiative includes innovations in payment systems, enhancing grassroots medical capabilities, and promoting industry collaboration to make technology more accessible [1] Company Initiatives - Jianfan Bio initiated the "919 Uremia Care Day" to build social consensus and create a closed loop of "original innovation - technology accessibility - social advocacy" [1] - The company exemplifies how a domestic enterprise in the medical technology field can empower social welfare through core technology, fulfilling the dual mission of "treating diseases and saving lives" while contributing to industrial growth [1] Event Details - The forum where the case study was presented was guided by the China Association for International Exchange of Personnel and organized by the Hainan Asia Public Welfare Research Institute along with several other institutions [1] - The event attracted over 600 participants from 16 countries and regions, including government representatives, international organization leaders, philanthropists, entrepreneurs, and scholars, to discuss Asian public welfare development [1] - The live broadcast of the forum garnered over 900,000 views, indicating significant interest in global sustainable development challenges [1]

Group 1 - The 2025 National Academic Forum on Severe Kidney Disease and Blood Purification Safety Quality Management was successfully held in Jinan, focusing on various aspects such as vascular access, metastatic calcification, and infection prevention in blood purification [3][5] - The forum emphasized the integration of multiple disciplines and the collaboration between academia and industry, aligning with the "Healthy China 2030" initiative [5][6] - Key discussions included the standardization of blood purification technology, the application of machine learning algorithms in quality monitoring, and innovative models in clinical demand-driven medical engineering integration [6] Group 2 - Notable experts from Japan shared insights on vascular access management and ultrasound-guided puncture techniques, highlighting Japan's advanced practices in blood dialysis [8][10] - The forum featured presentations from various leading professionals in the field, providing valuable knowledge and guidance to attendees [10][12] - The Jinan Weigao Kidney Hospital's chief expert introduced the current state of the domestic blood dialysis industry and the development of Weigao's services, which cover multiple provinces and serve nearly 10,000 patients [12]